Tumour necrosis factor-beta

Drug Profile

Tumour necrosis factor-beta

Alternative Names: Lymphotoxin

Latest Information Update: 14 Mar 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genentech
  • Developer Kanegafuchi Chemicals
  • Class Antihyperglycaemics; Antineoplastics; Antivirals; Cytokines; Tumour necrosis factors
  • Mechanism of Action Immunomodulators; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Type 1 diabetes mellitus

Most Recent Events

  • 17 Jul 1998 No-Development-Reported for Type-1 diabetes mellitus in Japan (Intraperitoneal)
  • 23 Jun 1998 Commercial data has been reviewed by Fujisawa
  • 03 Oct 1995 An in vivo study has been added to the Diabetes pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top